Signos OTC system pairs Dexcom CGM with AI app for weight management

An FDA-cleared system that pairs a Dexcom glucose sensor with an AI-driven app to guide weight management marks a notable shift in how people without diabetes access and interpret blood sugar data. The Signos Glucose Monitoring System, cleared for over-the-counter use, combines real-time glucose readings from the Dexcom sensor with personalized recommendations on diet, activity, sleep and stress. The development signals a broader move toward consumer-facing health technology that sits at the crossroads of wellness and medicine, with potential implications for reimbursement, regulation, and how users interpret metabolic signals.

The Signos system is designed to be used without a prescription and is aimed at individuals seeking to manage weight and overall metabolic health. It includes a subscription plan that covers continuous glucose monitoring sensors and access to the Signos app, which translates real-time glucose fluctuations into behavioral guidance. The company has positioned the product as a non-pharmacological path to weight management and health optimization, with plans that run roughly in the $129 to $139 per month range depending on the term chosen. The FDA clearance...